Advanced age represents one of the major risk factors for Parkinson’s Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson’s Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson’s Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson’s Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson’s Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson’s Disease patients, and healthy siblings of Parkinson’s Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson’s Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson’s Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson’s Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson’s Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson’s Disease.

Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients / Zago, E.; Dal Molin, A.; Dimitri, G. M.; Xumerle, L.; Pirazzini, C.; Bacalini, M. G.; Maturo, M. G.; Azevedo, T.; Spasov, S.; Gomez-Garre, P.; Perinan, M. T.; Jesus, S.; Baldelli, L.; Sambati, L.; Calandra-Buonaura, G.; Garagnani, P.; Provini, F.; Cortelli, P.; Mir, P.; Trenkwalder, C.; Mollenhauer, B.; Franceschi, C.; Lio, P.; Nardini, C.; Adarmes-Gomez, A.; Azevedo, T.; Bacalini, M. G.; Baldelli, L.; Bartoletti-Stella, A.; Bhatia, K. P.; Marta, B. -T.; Boninsegna, C.; Broli, M.; Dolores, B. -R.; Calandra-Buonaura, G.; Capellari, S.; Carrion-Claro, M.; Cilea, R.; Clayton, R.; Cortelli, P.; Molin, A. D.; De Luca, S.; De Massis, P.; Dimitri, G. M.; Doykov, I.; Escuela-Martin, R.; Fabbri, G.; Franceschi, C.; Gabellini, A.; Garagnani, P.; Giuliani, C.; Gomez-Garre, P.; Guaraldi, P.; Hagg, S.; Hallqvist, J.; Halsband, C.; Heywood, W.; Houlden, H.; Huertas, I.; Jesus, S.; Jylhava, J.; Labrador-Espinosa, M. A.; Licari, C.; Lio, P.; Luchinat, C.; Macias, D.; Macri, S.; Magrinelli, F.; Rodriguez, J. F. M.; Massimo, D.; Maturo, M. G.; Mengozzi, G.; Meoni, G.; Mignani, F.; Milazzo, M.; Mills, K.; Mir, P.; Mollenhauer, B.; Nardini, C.; Nassetti, S. A.; Pedersen, N. L.; Perinan-Tocino, M. T.; Pirazzini, C.; Provini, F.; Ravaioli, F.; Sala, C.; Sambati, L.; Scaglione, C. L. M.; Schade, S.; Schreglmann, S.; Spasov, S.; Strom, S.; Tejera-Parrado, C.; Tenori, L.; Trenkwalder, C.; Turano, P.; Valzania, F.; Ortega, R. V.; Williams, D.; Xumerle, L.; Zago, E.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 12:1(2022). [10.1038/s41598-022-05227-6]

Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients

Bacalini M. G.;Lio P.;Lio P.;
2022

Abstract

Advanced age represents one of the major risk factors for Parkinson’s Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson’s Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson’s Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson’s Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson’s Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson’s Disease patients, and healthy siblings of Parkinson’s Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson’s Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson’s Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson’s Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson’s Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson’s Disease.
2022
Aged; Aging; Biomarkers; Cohort Studies; Female; Humans; Male; MicroRNAs; Middle Aged; Parkinson Disease
01 Pubblicazione su rivista::01a Articolo in rivista
Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients / Zago, E.; Dal Molin, A.; Dimitri, G. M.; Xumerle, L.; Pirazzini, C.; Bacalini, M. G.; Maturo, M. G.; Azevedo, T.; Spasov, S.; Gomez-Garre, P.; Perinan, M. T.; Jesus, S.; Baldelli, L.; Sambati, L.; Calandra-Buonaura, G.; Garagnani, P.; Provini, F.; Cortelli, P.; Mir, P.; Trenkwalder, C.; Mollenhauer, B.; Franceschi, C.; Lio, P.; Nardini, C.; Adarmes-Gomez, A.; Azevedo, T.; Bacalini, M. G.; Baldelli, L.; Bartoletti-Stella, A.; Bhatia, K. P.; Marta, B. -T.; Boninsegna, C.; Broli, M.; Dolores, B. -R.; Calandra-Buonaura, G.; Capellari, S.; Carrion-Claro, M.; Cilea, R.; Clayton, R.; Cortelli, P.; Molin, A. D.; De Luca, S.; De Massis, P.; Dimitri, G. M.; Doykov, I.; Escuela-Martin, R.; Fabbri, G.; Franceschi, C.; Gabellini, A.; Garagnani, P.; Giuliani, C.; Gomez-Garre, P.; Guaraldi, P.; Hagg, S.; Hallqvist, J.; Halsband, C.; Heywood, W.; Houlden, H.; Huertas, I.; Jesus, S.; Jylhava, J.; Labrador-Espinosa, M. A.; Licari, C.; Lio, P.; Luchinat, C.; Macias, D.; Macri, S.; Magrinelli, F.; Rodriguez, J. F. M.; Massimo, D.; Maturo, M. G.; Mengozzi, G.; Meoni, G.; Mignani, F.; Milazzo, M.; Mills, K.; Mir, P.; Mollenhauer, B.; Nardini, C.; Nassetti, S. A.; Pedersen, N. L.; Perinan-Tocino, M. T.; Pirazzini, C.; Provini, F.; Ravaioli, F.; Sala, C.; Sambati, L.; Scaglione, C. L. M.; Schade, S.; Schreglmann, S.; Spasov, S.; Strom, S.; Tejera-Parrado, C.; Tenori, L.; Trenkwalder, C.; Turano, P.; Valzania, F.; Ortega, R. V.; Williams, D.; Xumerle, L.; Zago, E.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 12:1(2022). [10.1038/s41598-022-05227-6]
File allegati a questo prodotto
File Dimensione Formato  
Zago_Early_2022.pdf

accesso aperto

Note: https://www.nature.com/articles/s41598-022-05227-6.pdf
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.58 MB
Formato Adobe PDF
1.58 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1721233
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact